RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative

PHASE3CompletedINTERVENTIONAL
Enrollment

780

Participants

Timeline

Start Date

August 29, 2017

Primary Completion Date

July 7, 2021

Study Completion Date

July 7, 2021

Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
DRUG

Indacaterol/Glycopyrrolate

27.5/15.6 mcg active indacaterol/glycopyrrolate

DRUG

Placebo

27.5/15.6 mcg placebo

Trial Locations (16)

10021

Cornell University, New York

15213

University of Pittsburgh, Pittsburgh

19140

Temple University, Philadelphia

21224

Johns Hopkins University, Baltimore

27705

Duke University, Durham

35294

Universityof Alabama, Birmingham

48109

University of Michigan, Ann Arbor

52242

University of Iowa, Iowa City

55130

Minnesota Health partners, Saint Paul

55417

Minneapolis VA Medical Center, Minneapolis

60608

University of Illinois, Chicago

60657

Northwestern University, Chicago

84132

University of Utah, Salt Lake City

90095

University of California, Los Angeles

90502

LABIOMED at Harbor-UCLA Medical Center, Torrance

94143

University of California, San Francisco

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Michigan

OTHER

NCT02867761 - RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative | Biotech Hunter | Biotech Hunter